PULSE Registry: Lutetium-177Lu VIP (pluvict?), for patients with metastatic prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicountry, non-interventional, longitudinal registry that uses AI-enabled data extraction to collect real-world usage data on lutetium-177Lu vipivotide tetraxetan. The study aims to describe how the drug is used in routine practice among patients with metastatic prostate cancer. Data will be drawn from existing medical records to characterize patterns of administration, timing, and concomitant therapies. There are no planned interventions or experimental arms, and eligibility requires confirmed metastatic prostate cancer, PSMA positivity, and at least one prior dose of the therapy. Exclusion includes recent participation in an investigational study within specified windows. The study is sponsored by Novartis with Basel-based investigative sites.

Why it matters

Who can join: the full rules

Inclusion criteria:

Age ≥ 18 years at index date

* Diagnosis of mPC
* PSMA positive
* Received at least one dose of lutetium (177Lu) vipivotide tetraxetan on or after mPC diagnosis date

Exclusion criterion:

• Current or prior participation in an investigational study within the 30-day period immediately prior to and including the index date, or within five half-lives of the investigational product (whichever is longer)

Where it's running

• Novartis Investigative SIte
  Basel, Switzerland Recruiting

Study contacts

• Study coordinator: Novartis Pharmaceuticals
• Email: novartis.email@novartis.com
• Phone: +41613241111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• JANX013 and JANX007 combo in advanced prostate cancer

  A first-in-human study will test JANX013 together with JANX007 to see if this combination is safe and tolerable in adults with metastatic castration-resistant prostate cancer.

  Recruiting Phase 1 Janux Therapeutics · Nashville, Tennessee · NCT07813637

• PSMA PET-Staged Progression-Directed Radiotherapy for Limited Prostate Cancer Progression

  A real-world registry tests how well comprehensive progression-directed radiotherapy works for men with metastatic prostate cancer who show a small number of progressing lesions while on systemic therapy.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość, Lublin Voivodeship · NCT07691697

• Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer

  This registry follows men with new, limited metastatic prostate cancer who receive targeted radiotherapy to the prostate and all visible metastases to see how they do over time in real-world care.

  Recruiting Affidea Nu-med Center of Oncological DIagnostics and Therapy · Zamość, Lublin Voivodeship · NCT07686016

• PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer

  This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07650240

• First-in-human imaging test of the GRPR-targeted theranostic pair for advanced breast or prostate cancer

  This early feasibility study tests a GRPR-targeted imaging agent for PET and a low-dose radiopharmaceutical for SPECT in adults with advanced breast or prostate cancer to see if it is safe and can image tumors.

  Recruiting Early Phase 1 Integrated Haematology and Oncology Network · Perth, Western Australia · NCT07608848

• Combined treatment approach in metastatic prostate cancer using AZD2265 (FPI-2265) with palacaparib or docetaxel

  This study tests how AZD2265 (FPI-2265) with or without palacaparib or docetaxel works in men with metastatic castration-resistant prostate cancer who have already tried AR pathway inhibitors.

  Recruiting at 3 sites Phase 1/2 AstraZeneca · Duarte, California and 37 other locations · NCT07590934

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.